Precision Medicine Solution
SolaranRx precisely targets deadly melanoma tumors with a radiolabeled peptide, offering unique therapeutic potential with minimal side effects.
Company Overview
SolaranRx is focused on developing a new class of therapies and companion imaging agents to treat metastatic melanoma. It has developed a Precision Theranostic Platform™ that targets metastatic melanoma tumors with a radiolabeled peptide. It claims that the technology has a therapeutic potential with minimum side effects. SolaranRx is focused on developing its lead product SRX-1177, a novel peptide linked to a radioisotope that preferentially attaches to melanocortin-1 (MC1) receptors. The candidate has been granted Orphan Drug designation by the FDA based on compelling pre-clinical evidence.
The Powerful Science Behind SolaranRx
There are no curative treatments for metastatic melanoma. The only options currently on the market have significant potential for severe side effects, benefit a small subset of patients and are very costly. SolaranRx seeks to change this situation with a proprietary peptide technology platform that creates a novel clinical approach intended to improve patient’s lives and disease prognosis.
Company Profile
SolaranRx is developing a platform of therapies and companion imaging agents for metastatic melanoma, representing a game changer for both clinicians and patients.
Precision Medicine
Our lead product, SRX-1177, creates a new class of melanoma therapy, combining a novel peptide with a commercially available radioisotope into an injectable drug. Similar radiotherapies for other cancers are effective in up to 75% of patients.
Metastatic Melanoma
Nearly one million Americans have melanoma and 9,940 will die of the disease in 2015. With poor patient outcomes and no known cure for metastatic melanoma, the unmet need for effective therapies is significant.
Contact Us
Want to learn more about SolaranRx or have a question about our approach? Use the contact form and let’s start a conversation.